Raymond James & Associates Pa Vmed Inc. Transaction History

Raymond James & Associates

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	BUY	$0.22 - $0.5 $23,037 - $52,358	104,717 Added 316.91%	137,760 $41,000
Q4 2022 Feb 08, 2023	BUY	$0.41 - $18.6 $9,119 - $413,719	22,243 Added 205.95%	33,043 $15,000
Q3 2022 Oct 25, 2022	BUY	$0.57 - $34.65 $113 - $6,930	200 Added 1.89%	10,800 $9,000
Q2 2022 Aug 12, 2022	SELL	$0.85 - $1.41 $1,623 - $2,693	-1,910 Reduced 15.27%	10,600 $10,000
Q1 2022 May 11, 2022	SELL	$1.16 - $2.5 $5,932 - $12,785	-5,114 Reduced 29.02%	12,510 $17,000
Q4 2021 Feb 08, 2022	SELL	$2.46 - $8.74 $176,532 - $627,191	-71,761 Reduced 80.28%	17,624 $43,000
Q3 2021 Nov 02, 2021	BUY	$5.1 - $9.39 $240,781 - $443,320	47,212 Added 111.95%	89,385 $763,000
Q2 2021 Aug 11, 2021	BUY	$3.95 - $6.88 $166,583 - $290,150	42,173 New	42,173 $270,000

2.24M

Ticker PAVM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 90,999,104
Market Cap $93.7M
Description
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted ne...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.